Endeavor Health and GoPath Diagnostics launch genetic test for aggressive prostate cancer
Endeavor Health and GoPath Diagnostics have introduced a clinical genetic test designed to identify aggressive prostate cancer, supported by findings in peer-reviewed journals.
Researchers from Endeavor Health and GoPath Diagnostics have finalized a new genetic testing protocol aimed at identifying aggressive forms of prostate cancer. The test, which is now available for clinical use, utilizes genetic markers to provide a more detailed risk assessment for patients recently diagnosed with the disease.
Detailed findings regarding the efficacy and methodology of the test have been documented in the journals Prostate Cancer and Prostatic Disease and The Prostate. The research focuses on distinguishing between indolent and aggressive disease pathways, a critical challenge in minimizing unnecessary medical interventions for patients with low-risk conditions.
By incorporating this genetic analysis into the standard diagnostic workflow, clinicians aim to tailor treatment plans more effectively. This shift toward biomarker-based diagnostics reflects broader industry efforts to move away from one-size-fits-all screening and toward personalized oncology.